Evidence-Based Complementary and Alternative Medicine
Volume 2016 (2016), Article ID 8394850, 12 pages
http://dx.doi.org/10.1155/2016/8394850

Research Article

The Effectiveness of Traditional Chinese Medicine in Treating Patients with Leukemia

Yu-Jun Wang,¹ Chung-Chih Liao,² Hsuan-Ju Chen,3,4 Ching-Liang Hsieh,1,5 and Tsai-Chung Li6,7,8

¹Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan
²Graduate Institute of Chinese Medical Science, China Medical University, Taichung, Taiwan
³Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan
⁴College of Medicine, China Medical University, Taichung, Taiwan
⁵Department of Chinese Medicine, China Medical University Hospital, Taichung, Taiwan
⁶Research Center for Chinese Medicine & Acupuncture, China Medical University, Taichung, Taiwan
⁷Department of Healthcare Administration, College of Health Science, Asia University, Taichung, Taiwan
⁸Department of Public Health, College of Public Health, China Medical University, Taichung, Taiwan

Received 22 May 2016; Revised 15 August 2016; Accepted 14 September 2016

Academic Editor: Raffaele Capasso

Copyright © 2016 Yu-Jun Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

Leukemia is the most common malignancy among all childhood cancers and is associated with a low survival rate in adult patients. Since 1995, the National Health Insurance (NHI) program in Taiwan has been offering insurance coverage for Traditional Chinese Medicine (TCM), along with conventional Western medicine (WM). This study analyzes the status of TCM utilization in Taiwan, in both pediatric and adult patients with leukemia. A retrospective cohort study was conducted using population-based National Health Insurance Research Database of Registry of Catastrophic Illness, involving patient data from 2001 to 2010 and follow-up data through 2011. The effectiveness of TCM use was evaluated. Relevant sociodemographic data showed that both pediatric and adult patients who were TCM users one year prior to leukemia diagnosis were more likely to utilize TCM services for cancer therapy. A greater part of medical expenditure of TCM users was lower than that of TCM nonusers, except little discrepancy in drug fee of adult patients. The survival rate is also higher in TCM users. Altogether, these data show that TCM has the potential to serve as an adjuvant therapy when combined with conventional WM in the treatment of patients with leukemia.

1. Introduction

Leukemia originates in the bone marrow and results in the production of a large number of abnormal white blood cells. The four main subtypes of leukemia are acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myelogenous leukemia (CML) [1]. Leukemia is the most common malignancy diagnosed in children accounting for greater than 30% of all childhood cancers [2]. While ALL is the most prevalent cancer in childhood and also the first leading cause of death from cancer within 20 years of age [3], AML is more common in older adults [4]. Patients with leukemia may undergo chemotherapy or hematopoietic stem cell transplants, which are associated with massive physical suffering and economic burden [5, 6].

The National Health Insurance (NHI) program has offered insurance cover for Traditional Chinese Medicine (TCM) and conventional Western medicine (WM) since 1995. Several studies have demonstrated that TCM as adjuvant therapy can help improve the quality of life and alleviate the side effects associated with WM use. Importantly, it can enhance the efficacy of WM treatment against tumors and improve the survival rate [7–13]. For instance, one study indicated that TCM combined with chemotherapy significantly elevates survival rate and improves the quality of life in patients with advanced non-small-cell lung carcinoma [12]. Another observational study demonstrated that TCM as adjuvant therapy helps to lower the risk of mortality relative to “TCM nonusers” in advanced breast cancer [9]. Apart from case reports and standardized questionnaire surveys, there are few large-scale studies on TCM use among leukemia patients [14, 15]. Thus, our study aimed to explore the determinants of TCM utilization in both pediatric and adult leukemia patients and further evaluate the overall survival of patients.

2. Materials and Methods

2.1. Research Data Sources

The NHI program, initiated in 1995, currently covers nearly 99.6% of the residents in Taiwan. The Bureau of National Health Insurance has contracts and cooperative agreements with nearly 97% of all hospitals and 92% of all clinics. This study included National Health Insurance Research Database (NHIRD) claim datasets that are safe from counterfeits due to the severe penalties involved [16]. The NHIRD datasets used in this study consisted of registry for beneficiaries, ambulatory and inpatient care claims, and registry for catastrophic illness from 1999 to 2011. Besides these, the NHIRD database contains demographic data, dates of visits, International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnostic codes, complete prescription details, and expenditure incurred by the beneficiaries. Data for detailed diagnoses and treatments provided by physicians were included. On the other hand, all cancer cases registered in the catastrophic illness database were eligible for an exemption from copayment. Our study was approved by the Joint Institutional Review Board of Public Health, Social and Behavioral Science Committee, China Medical University and Hospital.

2.2. Study Population

Our population-based retrospective cohort study included newly diagnosed patients with leukemia (ICD-9-CM code 204–208) identified from the registry of catastrophic illness between January 1, 2001, and December 31, 2010. In Taiwan health care system, the diagnosis of leukemia cases was done by WM physicians and cannot be done by TCM physicians because all diagnosis tests, including regular blood routine test (CBC/DC), blood smear (observing blood cell morphology), bone marrow biopsy (observing bone marrow cell morphology), and symptoms and signs, can be performed only by WM physicians. The index date was the initial date of leukemia diagnosis and all patients were followed up through December 31, 2011, or until the patients’ death date within this interval or withdrawal from NHI. The index date was the date of first diagnosis. We analyzed 2,355 newly diagnosed pediatric patients (0–18 years old) and 10,208 newly diagnosed adult patients (19–80 years old) with leukemia. Patients who visited TCM physicians and used TCM at least once after being diagnosed with leukemia were deemed “TCM users” and the rest were deemed “TCM nonusers.”

2.3. Comorbidities and Classification of Expenditures

This study considered TCM and WM ambulatory care, including dates of visit, date of birth, patient gender, medical facility and department visited, prescribing physician, dispensing pharmacist, three items from the ICD-9-CM codes, primary procedure, type of copayment, and paid amounts. We also analyzed the coexisting diseases in the leukemia patients based on the ICD-9-CM codes. Types of expenditure included fees for consultation, treatment and medical supplies, diagnosis fee, and drug fee.

2.4. Sociodemographic Factors and Urbanization Levels of Residential Area

The sociodemographic factors included age, gender, insurance premium amount, and the insured unit. Pediatric patients were further divided into 3 subgroups: 0–6, 7–12, and 13–18 years. Similarly, the adult patients were also divided into 3 subgroups: 19–40, 41–60, and 61–80 years. The amount of insurance premium, determined from the individual working salary, was classified into four levels: <20,000, 20,000–39,999, 40,000–59,999, and >60,000 NT$/month. The residential areas of the study population comprised 6 areas: Northern area, Taipei, Central area, Southern area, Eastern area, and Kao-Ping area (Figure 1). Furthermore, the urbanization level of the townships in Taiwan was categorized according to educational level of the population, population density, the ratio of elder people, and occupation in general [17]. The insured unit included government, school, private enterprise, occupational member, farmer and fishermen, low-income household, and veterans.

Figure 1: The residential areas of the study population.

2.5. Statistical Analysis

All analyses were performed separately for the pediatric and adult patient groups. The continuous variables were evaluated using means, standard deviations, and 95% confidence interval (CI), whereas categorical variables were evaluated using the numbers, percentages, and 95% CI. To compare the differences in continuous variables between TCM users and nonusers, Student’s -test was used, whereas Chi-square test was used to analyze the categorical variables. Furthermore, the adjusted odds ratio (OR), calculated using a multivariate logistic regression analysis, was used to explore the determinants of TCM utilization. The Kaplan-Meier estimator with a log-rank test was applied to evaluate the effect of TCM use on overall survival. Pairwise comparisons of overall survival among groups of no, low, and high TCM use were adjusted by Bonferroni correction. All values were calculated using two-sided tests, and the threshold for statistical significance was set at . All analyses were performed using Statistical Analysis System (SAS) version 9.3 (SAS Institute Inc., Cary, NC, USA).

3. Results

3.1. Factors Associated with TCM Use

A total of 292 (12.40%) pediatric patients and 936 (9.17%) adult patients availed TCM outpatient services. In these leukemia patients, we observed that patients who were TCM users one year prior to the leukemia diagnosis and who resided in central area were more likely to utilize TCM services (Table 1). The mean numbers of days taking TCM in pediatric and adult leukemia patients were 184 (SD = 328) days and 107 (SD = 254) days, respectively. The mean outpatient department (OPD) visits for TCM in pediatric and adult leukemia patients were 20.3 (SD = 35.3) and 10.5 (SD = 22.8), respectively. The distributions of cancer type were similar between TCM users and nonusers in both pediatric and adult leukemia patients.

Table 1: Sociodemographic factors of pediatric and adult patients with leukemia according to use of TCM.

Characteristic
⁢Pediatric (,355)
⁢Adult (,208)

TCM users
TCM nonusers
Adjusted OR‡ 
(95% CI)
TCM users
TCM nonusers
Adjusted OR‡ 
(95% CI)

%

%

%

%

Number of patients
292

2,063

936

9,272

Age, years

    0–6
139
47.60
1,016
49.25
1.00

    7–12
89
30.48
480
23.27
1.10 (0.81–1.50)

    13–18
64
21.92
567
27.48
0.64 (0.46–0.89)

    19–40

274
29.27
2,199
23.72
1.00

    41–60

379
40.38
3,012
32.48
0.95 (0.80–1.13)

    61–80

284
30.34
4,061
43.80
0.60 (0.48–0.70)

    Means (SD)
8.03
(5.07)
8.41
(5.65)

51.26
(15.67)
55.39
(17.24)

Gender

    Female
129
44.18
843
40.86
1.00
428
45.73
3,740
40.34
1.00

    Male
163
55.82
1,220
59.14
0.83 (0.64–1.07)
508
54.27
5,532
59.66
0.86 (0.74–0.99)

TCM use one year prior to leukemia diagnosis

    TCM nonusers
180
61.64
1,523
73.82
1.00
437
46.69
6,048
65.23
1.00

    TCM users
112
38.36
540
26.18
1.62 (1.23–2.13)
499
53.31
3,224
34.77
1.97 (1.71–2.26)

Insured amount (NT/month)

    <20,000
286
97.95
2,035
98.64
1.00
610
65.17
6,736
72.65
1.00

    20,000–39,999
6
2.05
27
1.31
2.02 (0.79–5.15)
197
21.05
1,613
17.40
1.23 (1.02–1.47)

    40,000–59,999
0
0.00
1
0.05
—
101
10.79
735
7.93
1.48 (1.15–1.90)

    ≥60,000
—
—
—
—
—
28
2.99
188
2.03
1.65 (1.08–2.55)

Urbanization

    Level 1 (highest)
78
26.71
564
27.34
1.00
278
29.70
2,521
27.19
1.00

    Level 2
97
33.22
655
31.75
0.85 (0.59–1.24)
279
29.81
2,698
29.10
0.86 (0.70–1.04)

    Level 3
48
16.44
371
17.98
0.52 (0.32–0.82)
149
15.92
1,625
17.53
0.67 (0.53–0.85)

    Level 4
45
15.41
296
14.35
0.63 (0.39–1.02)
134
14.32
1,329
14.34
0.74 (0.58–0.96)

    Level 5 (lowest)
24
8.22
177
8.58
0.63 (0.34–1.14)
96
10.26
1,098
11.84
0.69 (0.51–0.94)

Residential area

    Northern
32
10.96
304
14.74
1.00
85
9.08
1,245
13.43
1.00

    Taipei
75
25.68
750
36.35
0.76 (0.46–1.24)
274
29.27
229
34.83
1.01 (0.77–1.34)

    Central
104
35.62
306
14.83
3.33 (2.12–5.23)
265
28.31
1,623
17.51
2.41 (1.85–3.14)

    Southern
36
12.33
324
15.71
1.17 (0.69–1.99)
163
17.41
1,372
14.80
1.95 (1.47–2.59)

    Eastern
3
1.03
42
2.04
0.73 (0.21–2.58)
27
2.88
261
2.82
1.78 (1.11–2.84)

    Kao-Ping
42
14.38
337
16.34
1.16 (0.70–1.92)
122
13.03
1,541
16.62
1.13 (0.84–1.52)

Insured unit

    Government, school employees
39
13.59
176
9.30
1.00
130
13.92
1,056
11.42
1.00

    Private enterprise employees
145
50.52
916
48.39
0.70 (0.47–1.05)
404
43.25
3,533
38.21
0.91 (0.73–1.13)

    Occupational member
37
12.89
342
18.07
0.47 (0.28–0.77)
198
21.20
1,973
21.34
0.87 (0.68–1.12)

    Farmers, fishermen
36
12.54
226
11.94
0.69 (0.40–1.18)
141
15.10
1,827
19.76
0.80 (0.60–1.07)

    Low-income households and veterans registered in local government agency
30
10.45
233
12.31
0.58 (0.34–0.98)
61
6.53
857
9.27
0.73 (0.52–1.02)

Number of days taking TCM, means (SD)
184
(328)
—
—

107
(254)
—
—

OPD visits for TCM, means (SD)
20.3
(35.3)
—
—

10.5
(22.8)
—
—

Cancer subtype

    Lymphoid leukemia
205
70.21
1,377
66.75
1.00
217
23.18
1,896
20.45
1.00

    Myeloid leukemia
79
27.05
609
29.52
1.10 (0.83–1.44)
649
69.34
6,670
71.94
0.85 (0.72–1.00)

    Uncertain
8
2.74
77
3.73
0.88 (0.42–1.85)
70
7.48
706
7.61
0.87 (0.65–1.15)

ICD-9-CM: lymphoid leukemia, 204.xx; myeloid leukemia, 205.xx.

TCM: Traditional Chinese Medicine; OR: odd ratio; SD: standard deviation; CI: confidence interval; OPD: outpatient department.

⁢, , and .

‡Adjusted ORs were from the model considering age, gender, visit one year ago, insured amount, urbanization, residential area, and insured unit.

3.2. Medical Institutes

TCM users within pediatric leukemia patients engaged private hospitals more often for outpatient services than TCM pediatric nonusers (42.15% versus 38.70%). Similar trend was also seen within adult leukemia patients (36.17% versus 34.20%). On the contrary, private clinics were more often engaged for outpatient services by TCM nonusers of pediatric patients when compared to TCM users (41.37% versus 35.22%) as well as by TCM adult nonusers (43.32% versus 41.13%) (Table 2).

Table 2: Distributions of outpatient service providers for pediatric and adult patients with leukemia during 2001–2011.

Outpatient services providers
TCM users
TCM nonusers
value for ²

Visits
Percentage (95% CI)
Visits
Percentage (95% CI)

Pediatric

Type of provider

<0.001

    Public hospitals
20,407
22.33 (22.06, 22.6)
80,522
19.47 (19.35, 19.59)

    Public Chinese medicine hospitals
20
0.02 (0.01, 0.03)
92
0.02 (0.02, 0.03)

    Private hospitals
38,522
42.15 (41.83, 42.47)
160,049
38.70 (38.55, 38.85)

    Private Chinese medicine hospitals
86
0.09 (0.07, 0.11)
191
0.05 (0.04, 0.05)

    Public clinics
160
0.18 (0.15, 0.2)
1,497
0.36 (0.34, 0.38)

    Private clinics
32,187
35.22 (34.91, 35.53)
171,108
41.37 (41.22, 41.52)

    Other medicine service providers
9
0.01 (0, 0.02)
103
0.02 (0.02, 0.03)

Total
91,391

413,562

Adult

Type of provider

<0.001

    Public hospitals
52,167
20.64 (20.49, 20.80)
354,202
19.77 (19.71, 19.83)

    Public Chinese medicine hospitals
400
0.16 (0.14, 0.17)
905
0.05 (0.05, 0.05)

    Private hospitals
91,396
36.17 (35.98, 36.36)
612,655
34.20 (34.13, 34.27)

    Private Chinese medicine hospitals
614
0.24 (0.22, 0.26)
4,044
0.23 (0.22, 0.23)

    Public clinics
3,782
1.5 (1.45, 1.54)
40,716
2.27 (2.25, 2.29)

    Private clinics
103,932
41.13 (40.94, 41.32)
776,052
43.32 (43.24, 43.39)

    Other medicine service providers
399
0.16 (0.14, 0.17)
3,026
0.17 (0.16, 0.17)

Total
252,690

1,791,600

TCM: Traditional Chinese Medicine; CI: confidence interval.

3.3. Coexisting Diseases

We observed that lymphoid leukemia and myeloid leukemia were the two major diagnoses in these leukemia patients. Lymphoid leukemia was common in children and myeloid leukemia was diagnosed mainly in adults. Acute upper and lower respiratory infections were commonly diagnosed in both pediatric and adult patients, irrespective of TCM use by the patients (Table 3).

Table 3: Top 5 disease codes among pediatric and adult leukemia patients during the years 2001–2011 for all outpatients visits.

Ranking
TCM users
TCM nonusers

Disease (Code)
Number
Percentage (95% CI)
Disease (Code)
Number
Percentage (95% CI)

Pediatric

    Total visits
91,391

413,562

    1
Lymphoid leukemia (204)
36,529
39.97 (39.65, 40.29)
Lymphoid leukemia (204)
138,518
33.49 (33.35, 33.64)

    2
Myeloid leukemia (205)
7,801
8.54 (8.35, 8.72)
Acute upper respiratory infections (465)
45,756
11.06 (10.97, 11.16)

    3
Acute upper respiratory infections (465)
6,873
7.52 (7.35, 7.69)
Myeloid leukemia (205)
34,551
8.35 (8.27, 8.44)

    4
Leukemia of unspecified cell type (208)
4,698
5.14 (5, 5.28)
Acute bronchitis and bronchiolitis (466)
15,506
3.75 (3.69, 3.81)

    5
Acute bronchitis and bronchiolitis (466)
2,962
3.24 (3.13, 3.36)
Acute sinusitis (461)
12,141
2.94 (2.88, 2.99)

Adult

    Total visits
252,690

1,791,600

    1
Myeloid leukemia (205)
55,031
21.78 (21.62, 21.94)
Myeloid leukemia (205)
264,653
14.77 (14.72, 14.82)

    2
Lymphoid leukemia (204)
19,336
7.65 (7.55, 7.76)
Acute upper respiratory infections (465)
97,491
5.44 (5.41, 5.47)

    3
Acute upper respiratory infections (465)
11,117
4.4 (4.32, 4.48)
Lymphoid leukemia (204)
76,117
4.25 (4.22, 4.28)

    4
Gingival and periodontal diseases (523)
5,680
2.25 (2.19, 2.31)
Diabetes mellitus (250)
56,042
3.13 (3.1, 3.15)

    5
Diseases of hard tissues of teeth (521)
5,123
2.03 (1.97, 2.08)
Essential hypertension (401)
53,009
2.96 (2.93, 2.98)

TCM: Traditional Chinese Medicine; CI: confidence interval.

3.4. Expenditures

According to our analysis, drug fee was the major component of all outpatient medical expenditures (Table 4). For both pediatric and adult leukemia patients, the average cost of total amount per visit was higher for TCM users than that of TCM nonusers. In adult leukemia patients, the average cost of drug fee per visit in TCM users was higher than that of TCM nonusers. Nevertheless, the differences in average costs between these two groups were indeed minimal (2,557.98 NT$ versus 2,535.07 NT$). The costs of other items per visit in TCM users in adult leukemia patients were significantly lower than those of TCM nonusers, including fees for consultation, treatment, medical supply, and diagnosis fee. In pediatric patients, the average cost per visit in TCM users was consistently higher than that of TCM nonusers for all items including fees for consultation, treatment, medical supply, diagnosis fee, and drug fee.

Table 4: Expenditures for outpatient services for pediatric and adult leukemia patients (NT) during the period 2001–2011.

Characteristic
TCM users
TCM nonusers
value

Total
Percentage
(95% CI)
Average cost per visit
(95% CI)
Total
Percentage
(95% CI)
Average cost per visit
(95% CI)

Pediatric

Outpatient visits
91,391

413,562

Fees for consultation, treatment, and medical supplies
52,088,100
38.09 (38.08, 38.1)
569.95 (559.62, 580.28)
245,838,958
32.74 (32.73, 32.74)
594.45 (589.71, 599.19)

Diagnosis fee
19,341,052
14.14 (14.14, 14.15)
211.63 (210.86, 212.4)
88,180,707
11.74 (11.74, 11.74)
213.22 (212.84, 213.61)

Drug fee
65,311,809
47.76 (47.75, 47.77)
714.64 (680.14, 749.15)
416,969,010
55.52 (55.52, 55.53)
1008.25 (986.8, 1029.7)

Total amount
136,740,961
100
1496.22 (1459.61, 1532.83)
750,988,675
100
1815.92 (1793.74, 1838.1)

Adult

Outpatient visits
252,690

1,791,600

Fees for consultation, treatment, and medical supplies
170,260,064
19.55 (19.55, 19.56)
673.79 (663.88, 683.70)
1,282,955,508
20.66 (20.66, 20.66)
716.10 (711.68, 720.52)

Diagnosis fee
54,059,202
6.21 (6.21, 6.21)
213.93 (213.46, 214.41)
386,270,204
6.22 (6.22, 6.22)
215.60 (215.42, 215.78)

Drug fee
646,375,253
74.24 (74.23, 74.24)
2557.98 (2512.05, 2603.91)
4,541,817,387
73.12 (73.12, 73.13)
2535.07 (2516.85, 2553.29)
−0.91

Total amount
870,694,519
100
3445.70 (3398.59, 3492.81)
6,211,043,099
100
3466.77 (3447.99, 3485.55)
0.81

.

3.5. Most Commonly Prescribed TCM Single and Formula Products

Details of the TCM single and formula products most frequently prescribed by TCM physicians are shown in Table 5. In pediatric leukemia patients, Radix Astragali membranaceus was the most commonly prescribed TCM single product, followed by Bulbus Fritillariae thunbergii, and Herba Hedyotis diffusa. Moreover, Xiang Sha Liu Jun Zi Tang was the most frequently prescribed TCM formula product, followed by Yu Ping Feng San and Zuo Gui Wan. The top three most commonly used TCM single products for adult leukemia patients were as follows, from the most common to the least: Radix Astragali membranaceus, Radix et Rhizoma Salviae miltiorrhizae, and Fructus Ligustri Lucidi. Moreover, the top three most commonly prescribed TCM single products were Gui Pi Tang, Liu Wei Di Huang Wan, and Zuo Gui Wan.

Table 5: Top ten formula CHPs and single CHPs prescribed by TCM physicians to treat pediatric and adult patients with leukemia in Taiwan, 2000–2011.

Single CHPs
Formula CHPs

Name
Number, frequency (%)
Name
Number, frequency (%)

Pediatric
Radix Astragali membranaceus
103 (5.80)
Xiang Sha Liu Jun Zi Tang
36 (7.86)

Bulbus Fritillariae thunbergii
87 (4.90)
Yu Ping Feng San
27 (5.90)

Herba Hedyotis diffusa
74 (4.16)
Zuo Gui Wan
25 (5.46)

Radix Scutellariae baicalensis
65 (3.66)
Bu Zhong Yi Qi Tang
24 (5.24)

Radix Puerariae lobatae
57 (3.21)
Shen Ling Bai Zhu San
20 (4.37)

Radix Glycyrrhizae uralensis
52 (2.93)
Bao He Wan
18 (3.93)

Herba Houttuyniae cordata
45 (2.53)
Xin Yi San
16 (3.49)

Semen Ziziphi Spinosi
34 (1.91)
Ma Zi Ren Wan
16 (3.49)

Rhizoma Polygonati odorati
32 (1.80)
Liu Wei Di Huang Wan
14 (3.06)

Herba Scutellariae barbatae
29 (1.63)
Ge Gen Tang
14 (3.06)

Adult
Radix Astragali membranaceus
173 (4.07)
Gui Pi Tang
83 (6.18)

Radix et Rhizoma Salviae miltiorrhizae
133 (3.13)
Liu Wei Di Huang Wan
53 (3.95)

Fructus Ligustri Lucidi
108 (2.54)
Zuo Gui Wan
39 (2.91)

Sargentodoxa Cuneata
86 (2.02)
Gui Lu Er Xian Jiao
39 (2.91)

Herba Hedyotis diffusa
82 (1.93)
Sheng Mai San
36 (2.68)

Rhizoma Dioscoreae polystachya
71 (1.67)
Jia Wei Xiao Yao San
35 (2.61)

Bulbus Fritillaria thunbergii
69 (1.62)
Xue Fu Zhu Yu Tang
27 (2.01)

Cortex Lycii Radicis
63 (1.48)
Xiang Sha Liu Jun Zi Tang
26 (1.94)

Radix Glycyrrhizae uralensis
59 (1.39)
Xin Yi Qing Fei Tang
25 (1.86)

Semen Ziziphi Spinosae
58 (1.36)
Ren Shen Yang Rong Tang
24 (1.79)

TCM: Traditional Chinese Medicine; CHPs: Chinese herb products.

3.6. Overall Survival

We found that the overall survival rate was higher in TCM users compared to TCM nonusers in both pediatric and adult patients with leukemia (both ) (Figure 2). During the 10 years that we followed, both pediatric and adult patients with leukemia who were TCM users had near 10% higher survival probability in comparison to the corresponding group of TCM nonusers patients. To further examine whether the overall survival rates were influenced by the number of days taking TCM and number of OPD visits for TCM use, we categorized these two variables using their median values as cutoff points (Figures 3 and 4). We observed that the overall survival rates were significantly different in subgroups of number of days taking TCM and OPD visits for TCM use in both pediatric and adult patients with leukemia (all ). We observed a dose-response relationship among three subgroups of TCM use according to either patients with number of days taking TCM or number of OPD visits for TCM use. The highest overall survival rates were found in patients with high number of days taking TCM (≥42.5 for pediatric patients and ≥28 for adult patients), which were significantly higher than those with low number of days taking TCM (<42.5 for pediatric patients and <28 for adult patients) ( for pediatric patients and for adult patients) and were also significantly higher than those who were TCM nonusers (both for pediatric and adult patients). The differences in overall survival curves were different between patients with low number of days taking TCM and TCM nonusers ( and <0.001 for pediatric and adult patients, resp.). Similarly, we observed significant pairwise differences in overall survival function among three subgroups of TCM use based on number of OPD visits.

(a) Pediatric

(b) Adult

Figure 2: Kaplan-Meier curves of overall survival in patients with leukemia based on TCM use during the follow-up period.

(a) Pediatric

(b) Adult

Figure 3: Kaplan-Meier curves of overall survival in patients with leukemia based on number of drug days for TCM use during the follow-up period. (a) TCM nonusers versus TCM user: days taking TCM < 42.5, . TCM nonusers versus TCM user: days taking TCM ≥ 42.5, . TCM user: days taking TCM < 42.5 versus TCM user: days taking TCM ≥ 42.5, . (b) TCM nonusers versus TCM user: days taking TCM < 28, . TCM nonusers versus TCM user: days taking TCM, . TCM user: days taking TCM < 28 versus TCM user: days taking TCM ≥ 28, .

(a) Pediatric

(b) Adult

Figure 4: Kaplan-Meier curves of overall survival in patients with leukemia based on number of outpatient department (OPD) visits for TCM use during the follow-up period. (a) TCM nonusers versus TCM user: OPD < 6, ; TCM nonusers versus TCM user: OPD ≥ 6, ; TCM user: OPD < 42.5 versus TCM user: OPD ≥ 6, . (b) TCM nonusers versus TCM user: OPD < 3, ; TCM nonusers versus TCM user: OPD ≥ 3, ; TCM user: OPD < 3 versus TCM user: OPD ≥ 3, .

4. Discussion

This study investigated the potential of TCM use as an adjuvant therapy for leukemia patients, both pediatric and adult, in Taiwan undergoing treatment with WM. The determinants for TCM utilization for leukemia patients in Taiwan, such as medical expenditure, and therapeutic effects were only scarcely reported in the past [18]. Our study shows that the combination therapy using TCM and WM for patients with leukemia does not cause additional financial burden relative to using WM only. Importantly, TCM use is associated with longer survival.

We observed that TCM utilization was more prevalent in pediatric leukemia patients rather than adults. We assume that children can barely tolerate the extremely uncomfortable symptoms and feelings accompanying chemotherapy, as previously suggested [19]. Studies show that TCM can alleviate adverse effects of WM and improve quality of life in cancer patients [7, 10, 11, 13]. Andersen’s health behavior model, which is advocated by many scholars of sociology and public health, claims that the use of health services is determined by predisposing factors, enabling factors, and need factors [20]. In our study, significant factors for TCM use included predisposing factors of gender and health beliefs, such as TCM use one year prior to leukemia diagnosis. Enabling factors observed were height of medical insurance, residential area, and urbanization level, which were similar to those reported by Liao et al. [21, 22]. On the other hand, a particularly higher prevalence of TCM utilization was observed in central Taiwan, which has the highest per capita ratio of TCM physicians.

Radix Astragali membranaceus and Fructus Ligustri Lucidi were in the top 3 herbs for adult users and Radix Astragali membranaceus was the top one herbs for pediatric users. Both of these herbs have a function that increases white blood cell count [23]. Due to the indication of leukemia being a consistently elevated white blood cell count, some physicians thought using the herbs that increase white blood cell count is not recommended because of the potential exacerbation of leukemia. Given the findings of the present study, these herbs may increase healthy WBC without aggravating the leukemia. This can be supported by the prior studies of these two herbs demonstrating that they bolster host immune response for cytotoxic activity by promoting apoptosis of tumor cells and may help the recovery from chemotherapy or radiation treatments [18, 24–27]. The findings of the present study provide important information for TCM physicians and patients with leukemia.

The National Health Insurance program was started on March 1, 1995. In 2011, 22.60 million out of 22.96 million Taiwan residents were enrolled in this program. The comprehensive NHI database is considered an appropriate source to assess certain diseases. In addition, the NHI database provides abundant sample population size and details in studies, eliminating the bias associated with a limited sample size.

Our study has several limitations, though. Firstly, some patients visiting TCM physicians preferred to receive decoction formulations of Chinese medicine, which were self-paid and not covered by the NHI program. In addition, about 10% of the TCM clinics were not contracted to the NHI because of the low reimbursement rates provided by the NHI. Therefore, the prevalence of TCM use and costs of outpatient visits could be underestimated. Secondly, we only explored the efficacy of general TCM utilization, including overall survival, but we did not consider the subtypes of leukemia and TCM prescriptions, which should be investigated in further studies. Last, the database does not contain information on daily activity, dietary habits, and body mass index, which may also be factors for TCM utilization and health care costs. Further studies considering the above information are therefore warranted.

5. Conclusion

Our study investigated the TCM utilization and prevalence among pediatric and adult patients with leukemia in Taiwan. It shows that TCM as adjuvant therapy combined with WM may indeed alleviate adverse symptoms, improve quality of life, and prolong overall survival, without incurring excess medical expenditure. This line of study in the future should aim at ruling out the possible confounders such as diet, lifestyle behaviors of exercise, and psychological status. The results of our study could be useful to health-policy decision makers as well as clinical practitioners while considering the integration of TCM with WM.

Competing Interests

The authors declare that there is no conflict of interests regarding the publication of this manuscript.

Authors’ Contributions

Yu-Jun Wang and Chung-Chih Liao contributed equally to this work.

Acknowledgments

The Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW105-TDU-B-212-133019), China Medical University Hospital, Academia Sinica Taiwan Biobank Stroke Biosignature Project (BM10501010037), NRPB Stroke Clinical Trial Consortium (MOST 105-2325-B-039-003), Tseng-Lien Lin Foundation, Taichung, Taiwan, Taiwan Brain Disease Foundation, Taipei, Taiwan, and Katsuzo and Kiyo Aoshima Memorial Funds, Japan, supported this study.

References

A. Redaelli, J. M. Stephens, B. L. Laskin, C. L. Pashos, and M. F. Botteman, “The burden and outcomes associated with four leukemias: AML, ALL, CLL and CML,” Expert Review of Anticancer Therapy, vol. 3, no. 3, pp. 311–329, 2003.

M. Belson, B. Kingsley, and A. Holmes, “Risk factors for acute leukemia in children: a review,” Environmental Health Perspectives, vol. 115, no. 1, pp. 138–145, 2007.

S. P. Hunger and C. G. Mullighan, “Acute lymphoblastic leukemia in children,” The New England Journal of Medicine, vol. 373, no. 16, pp. 1541–1552, 2015.

A. M. Almeida and F. Ramos, “Acute myeloid leukemia in the older adults,” Leukemia Research Reports, vol. 6, pp. 1–7, 2016.

A. K. Burnett, N. H. Russell, R. K. Hills et al., “Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial,” Journal of Clinical Oncology, vol. 31, no. 27, pp. 3360–3368, 2013.

S. Frey, C. R. Blankart, and T. Stargardt, “Economic burden and quality-of-life effects of chronic lymphocytic leukemia: a systematic review of the literature,” PharmacoEconomics, vol. 34, no. 5, pp. 479–498, 2016.

S. Chen, A. Flower, A. Ritchie et al., “Oral Chinese herbal medicine (CHM) as an adjuvant treatment during chemotherapy for non-small cell lung cancer: a systematic review,” Lung Cancer, vol. 68, no. 2, pp. 137–145, 2010.

J. S. Jacobson, S. B. Workman, and F. Kronenberg, “Research on complementary/alternative medicine for patients with breast cancer: a review of the biomedical literature,” Journal of Clinical Oncology, vol. 18, no. 3, pp. 668–683, 2000.

Y.-W. Lee, T.-L. Chen, Y.-R. V. Shih et al., “Adjunctive traditional Chinese medicine therapy improves survival in patients with advanced breast cancer: a population-based study,” Cancer, vol. 120, no. 9, pp. 1338–1344, 2014.

S. G. Li, H. Y. Chen, C. S. Ou-Yang et al., “The efficacy of chinese herbal medicine as an adjunctive therapy for advanced non-small cell lung cancer: a systematic review and meta-analysis,” PLoS ONE, vol. 8, no. 2, Article ID e57604, 2013.

M. Paul, B. Davey, B. Senf et al., “Patients with advanced cancer and their usage of complementary and alternative medicine,” Journal of Cancer Research and Clinical Oncology, vol. 139, no. 9, pp. 1515–1522, 2013.

Z. Y. Xu, C. J. Jin, C. C. Zhou et al., “Treatment of advanced non-small-cell lung cancer with Chinese herbal medicine by stages combined with chemotherapy,” Journal of Cancer Research and Clinical Oncology, vol. 137, no. 7, pp. 1117–1122, 2011.

J. Yarney, A. Donkor, S. Y. Opoku et al., “Characteristics of users and implications for the use of complementary and alternative medicine in Ghanaian cancer patients undergoing radiotherapy and chemotherapy: A Cross- Sectional Study,” BMC Complementary and Alternative Medicine, vol. 13, article 16, 2013.

T. Elsner, R. Muecke, O. Micke et al., “Survey on the worldwide chronic myeloid leukemia advocates network regarding complementary and alternative medicine,” Journal of Cancer Research and Clinical Oncology, vol. 139, no. 6, pp. 1025–1031, 2013.

M. Hensel, M. Zoz, and A. D. Ho, “Complementary and alternative medicine in patients with chronic lymphocytic leukemia,” Supportive Care in Cancer, vol. 17, no. 1, pp. 47–52, 2009.

H.-F. Chen, C.-A. Ho, and C.-Y. Li, “Age and sex may significantly interact with diabetes on the risks of lower-extremity amputation and peripheral revascularization procedures: evidence from a cohort of a half-million diabetic patients,” Diabetes Care, vol. 29, no. 11, pp. 2409–2414, 2006.

C.-C. Lin, C.-I. Li, C.-Y. Hsiao et al., “Time trend analysis of the prevalence and incidence of diagnosed type 2 diabetes among adults in Taiwan from 2000 to 2007: a population-based study,” BMC Public Health, vol. 13, no. 1, article 318, 2013.

L. H. Huang, Q. J. Yan, N. K. Kopparapu, Z. Q. Jiang, and Y. Sun, “Astragalus membranaceus lectin (AML) induces caspase-dependent apoptosis in human leukemia cells,” Cell Proliferation, vol. 45, no. 1, pp. 15–21, 2012.

F. Naja, M. Alameddine, M. Abboud, D. Bustami, and R. Al Halaby, “Complementary and alternative medicine use among pediatric patients with leukemia: the case of Lebanon,” Integrative Cancer Therapies, vol. 10, no. 1, pp. 38–46, 2011.

R. M. Andersen, “Revisiting the behavioral model and access to medical care: does it matter?” Journal of Health and Social Behavior, vol. 36, no. 1, pp. 1–10, 1995.

Y.-H. Liao, C.-C. Lin, T.-C. Li, and J.-G. Lin, “Utilization pattern of traditional Chinese medicine for liver cancer patients in Taiwan,” BMC Complementary and Alternative Medicine, vol. 12, article 146, 2012.

Y.-H. Liao, J.-G. Lin, C.-C. Lin, and T.-C. Li, “Distributions of usage and the costs of conventional medicine and traditional Chinese medicine for lung cancer patients in Taiwan,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 984876, 11 pages, 2013.

H. Yeung, Handbook of Chinese Herbs and Formulas, Institute of Chinese Medicine, Los Angeles, Calif, USA, 1985.

B. Hu, Q. Du, S. Deng et al., “Ligustrum lucidum Ait. fruit extract induces apoptosis and cell senescence in human hepatocellular carcinoma cells through upregulation of p21,” Oncology Reports, vol. 32, no. 3, pp. 1037–1042, 2014.

Y.-L. Kuo, C.-H. Chen, T.-H. Chuang et al., “Gene expression profiling and pathway network analysis predicts a novel antitumor function for a botanical-derived drug, PG2,” Evidence-Based Complementary and Alternative Medicine, vol. 2015, Article ID 917345, 15 pages, 2015.

Z. Pang, Z.-Y. Zhou, W. Wang et al., “The advances in research on the pharmacological effects of Fructus Ligustri Lucidi,” BioMed Research International, vol. 2015, Article ID 281873, 5 pages, 2015.

P. Zhang, H. Li, D. Chen, J. Ni, Y. Kang, and S. Wang, “Oleanolic acid induces apoptosis in human leukemia cells through caspase activation and poly(ADP-ribose) polymerase cleavage,” Acta Biochimica et Biophysica Sinica, vol. 39, no. 10, pp. 803–809, 2007.